Total Utang marang Modal Salarius (SLRX)

Salarius Pharmaceuticals, Inc. - logo grafis emiten SLRX

The market for epigenetic therapies for rare oncological diseases is currently in the early trial stage amid high demand from clinics. A retrospective of Salarius Pharmaceuticals (SLRX) share prices shows that the separate_debt_total_eq metric is 0.00. The business focuses on developing drugs for adults and children with Ewing sarcoma, targeting the global solid tumor market; however, operations are subject to the risks of trial failure and fierce competition.

salariuspharma.com (SLRX): Rasio Utang marang Ekuitas saka 04.07.2022 nganti 08.01.2026

Rincian metrik lan analitis perusahaan Salarius Pharma (SLRX)

- rega saham lan konsensus proyeksi valuasi:
Rega saham Salarius Pharmaceuticals, Inc.|SLRX - Target konsensus
- rincian kapitalisasi pasar:
Kapitalisasi pasar Salarius Pharmaceuticals|SLRX - Nilai Perusahaan
- indikator kapitalisasi buku:
Aset Bersih saben Siji Saham Salarius Pharmaceuticals|SLRX - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku salariuspharma.com|SLRX - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Total Utang marang Modal Salarius Pharmaceuticals|SLRX - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Salarius Pharmaceuticals|SLRX - Kewajiban utang agregat|Utang marang nilai buku Salarius Pharmaceuticals|SLRX - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Salarius Pharmaceuticals|Indikator likuiditas cepet salariuspharma.com
- data bathi resik lan rasio valuasi:
SLRX - Bathi resik
Pambiji fundamental perusahaan:Salarius Pharmaceuticals, Inc.
Produk dadi Salarius Pharmaceuticals

For a fundamental valuation of Salarius Pharmaceuticals (SLRX), understanding the balance between debt load and equity is critical. This indicator measures the proportion of borrowed funds within the capital structure, while the shifting ratio of financial debt to equity demonstrates the company's ability to fund costly clinical trials for oncology drugs without risking bankruptcy due to excessive leverage.

Analisis pesaing Salarius Pharmaceuticals

ONC (BeiGene) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Halozyme Therapeutics, Inc. (HALO)|Total Utang marang Modal RVMD|Total Utang marang Modal Ascentage Pharma Corp (AAPG)|Utang marang Ekuitas CG Oncology, Inc. CGON|URGN: Rasio Utang marang Ekuitas|Bicara Therapeutics - Total Utang marang Modal|Personalis Inc (PSNL) - Rasio Total Utang marang Ekuitas|ERAS: Total Utang marang Modal|Utang marang Modal Delcath Corp (DCTH)|Utang marang Ekuitas Y-mAbs Therapeutics|AURA: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas CADL (Candel Therapeutics)|ARAY (Accuray Inc) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal SLS (SELLAS Life Sciences Group)|ACTU - Rasio Total Utang marang Ekuitas|CTOR: Rasio Total Utang marang Ekuitas|HURA - Total Utang marang Modal|Protara Therapeutics, Inc. (TARA) - Utang marang Ekuitas|Fate Therapeutics Inc - Rasio Kabeh Utang marang Dana Pribadi|WHWK (Aadi Bioscience, Inc.) - Total Utang marang Modal|Utang marang Modal TScan TCRX|Utang marang Ekuitas Champions Oncology (CSBR)|Koefisien Total Utang marang Modal xbiotech.com|Total Utang marang Modal CVM (CEL-SCI)|Total Utang marang Modal OS Therapies Inc. OSTX|RADX - Utang marang Ekuitas|ARTV: Utang marang Ekuitas|ANL: Total Utang marang Modal|verupharma.com (VERU) - Total Utang marang Modal|Utang marang Ekuitas Tempest Therapeutics, Inc.|XLO: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal RENB|Koefisien Total Utang marang Modal muraloncology.com|Kairos Pharma - Rasio Total Utang marang Ekuitas|Total Utang marang Modal OnKure Therapeutics, Inc. OKUR|GDTC - Utang marang Ekuitas|Koefisien Total Utang marang Modal Curis, Inc. CRIS|APLM (apollomicsinc.com) - Rasio Total Utang marang Ekuitas|Tharimmune Corporation - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Advanced Biomed Inc.|genprex.com - Utang Agregat marang Ekuitas|Total Utang marang Modal CLDI|SBFM (Sunshine Biopharma Inc.) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal XBIO (Xenetic Biosciences, Inc.)|Total Utang marang Modal Kitov Pharma PPBT|AONC - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi BGNE (beigene.com)|Checkpoint Therapeutics, Inc. (CKPT) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas elevationoncology.com|ICAD (iCAD Inc.) - Total Utang marang Modal|Total Utang marang Modal Ikena|Total Utang marang Modal NTBL|Rasio Total Utang marang Ekuitas viracta.com VIRX|Total Utang marang Modal MOR (MorphoSys)|NAYA Biosciences Inc (NAYA) - Utang marang Modal|AAPGV: Rasio Total Utang marang Ekuitas